IL6 and rheumatoid arthritis: Contrarily, significant different proportions of responders were found in RA patients under both CTLA-4 and IL-6-inhibitors with or without DMARD/CCS therapy, compared to HCWs (p=0.0018 and p<0.0001, respectively) (Table 2).